Valuation: Scandinavian ChemoTech AB

Capitalization 8.75Cr 97.28L 82.71L 76.83L 72L 1.34Cr 89Cr 1.42Cr 3.47Cr 42Cr 3.65Cr 3.57Cr 155.3Cr P/E ratio 2025 *
-
P/E ratio 2026 * -
Enterprise value 8.75Cr 97.28L 82.71L 76.83L 72L 1.34Cr 89Cr 1.42Cr 3.47Cr 42Cr 3.65Cr 3.57Cr 155.3Cr EV / Sales 2025 *
6.38x
EV / Sales 2026 * 3.94x
Free-Float
61.98%
Yield 2025 *
-
Yield 2026 * -
More valuation ratios * Estimated data
Dynamic Chart
1 day+11.61%
1 week-9.64%
Current month-25.30%
1 month-19.01%
3 months-22.52%
6 months+89.39%
Current year-25.30%
More quotes
1 week 3
Extreme 3
4.31
1 month 3
Extreme 3
5.48
Current year 3
Extreme 3
5.36
1 year 0.88
Extreme 0.88
7.76
3 years 0.88
Extreme 0.88
9.59
5 years 0.88
Extreme 0.88
41
10 years 0.88
Extreme 0.88
84
More quotes
Manager TitleAgeSince
Chief Executive Officer 52 01/01/2015
Director of Finance/CFO 60 01/01/2020
Chief Tech/Sci/R&D Officer - 06/10/2022
Director TitleAgeSince
Director/Board Member 52 01/01/2015
Director/Board Member 72 01/01/2020
Director/Board Member 73 01/01/2020
More insiders
Change 5d. change 1-year change 3-years change Capi.($)
+11.61%-9.64%+212.50%-42.66% 86.11L
+0.50%+2.83%+11.59%+7.71% 24TCr
+0.40%-3.83%-12.96%+104.78% 19TCr
-0.81%+0.90%-1.65%-12.51% 17TCr
-0.46%-2.61%-9.53%+100.11% 14TCr
+1.10%-6.25%-17.98%-8.37% 5.69TCr
-0.82%+1.61%+20.68%+6.50% 4.94TCr
-0.82%-5.00%-9.14%-11.09% 3.96TCr
-1.52%-1.60%+3.05%+8.78% 3.78TCr
+0.97%-4.00%-6.24%+22.64% 3.69TCr
Average +1.21%-3.54%+19.03%+17.59% 9.52TCr
Weighted average by Cap. +0.33%-0.92%-1.78%+35.01%
See all sector performances

Financials

2025 *2026 *
Net sales 1.37Cr 15.25L 12.96L 12.04L 11.28L 21.01L 14Cr 22.28L 54.39L 6.6Cr 57.17L 55.98L 24Cr 2.22Cr 24.71L 21.01L 19.52L 18.29L 34.06L 23Cr 36.12L 88.17L 11Cr 92.67L 90.75L 39Cr
Net income -65L -7L -6L -6L -5L -10L -6.61Cr -10.56L -25.77L -3.13Cr -27.08L -26.52L -12Cr 12L 1L 1L 1L 98.7T 2L 1.22Cr 2L 5L 57.74L 5L 5L 2.13Cr
Net Debt - -
More financial data * Estimated data
Logo Scandinavian ChemoTech AB
Scandinavian ChemoTech AB is a Sweden-based company, which is primarily engaged in the healthcare industry. The Company is focused on cancer treatment and manufactures specialized medical equipment. The Company's product IQWave is an electrochemotherapy (ECT) device. The IQWave system enhances the effects of the chemotherapeutic substance by opening up small pores in the tumor cells, giving the injected chemotherapeutic substance (no more than 15 IU of bleomycin) direct access to the DNA of the target cells. Among the product's applications are hypernephroma, kaposi sarcoma, transitional cell carcinoma, head and neck squamous cell carcinoma, malignant melanoma, basal cell carcinoma. The treatment can be used for cutaneous as well as subcutaneous tumors.
Employees
1
More about the company
Date Price Change Volume
22/26/22 3.750 kr +11.61% 51,150
21/26/21 3.360 kr -4.82% 90,801
20/26/20 3.530 kr -0.56% 21,445
19/26/19 3.550 kr -8.97% 1,86,096
16/26/16 3.900 kr -4.41% 10,285

Delayed Quote Nasdaq Stockholm, January 22, 2026 at 10:30 pm IST

More quotes

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Equities
  3. CMOTEC B Stock